Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Study Of Revlimid And Vidaza In Higher-Risk MDS Is Well-Tolerated And Has High Activity (Medical News Today) |
 |
 |
|
Celgene International Sarl (NASDAQ: CELG) reported that results of a Phase I study combining REVLIMID and VIDAZA in patients with higher-risk myelodysplastic syndromes (MDS) found that the combination of these two therapies is well tolerated and has high activity. The data were reported during the 50th Annual Meeting of the American Society of Hematology. |
